Skin Toxicity Due to Mercaptopurine in Maintenance Therapy Among Children With Acute Lymphoblastic Leukemia

被引：1

作者：

Higgerson, Kayeleigh ^{[1
,2
]}

Flatt, Terrie ^{[1
]}

机构：

[1] Childrens Mercy Hosp, BMT, Dept Pediat Hematol Oncol, Kansas City, MO USA

[2] Childrens Mercy Hosp, 2401 Gillham Rd, Kansas City, MO 64108 USA

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2023年 / 45卷 / 04期

关键词：

mercaptopurine; acute lymphoblastic leukemia; skin toxicity; allopurinol; thiopurine metabolites; 6MMPN; ALLOPURINOL; METABOLITES; 6-MERCAPTOPURINE;

D O I：

10.1097/MPH.0000000000002667

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mercaptopurine is a crucial component in the treatment of acute lymphoblastic leukemia. It is associated with toxicities that can delay treatment. Mercaptopurine is metabolized into 6-thioguanine nucleotides and 6-methylomercaptopurine nucleotides (6MMPN). Accumulation of 6MMPN has previously been associated with hepatotoxicity, pancreatitis, and hypoglycemia. However, skin toxicity has rarely been reported. We report 5 cases of elevated 6MMPN levels associated with cutaneous manifestations.

引用

页码：E514 / E517

页数：4

共 50 条

[21] Patients' Adherence in the Maintenance Therapy of Children and Adolescents with Acute Lymphoblastic Leukemia
Kremeike, K.
Juergens, C.
Alz, H.
Reinhardt, D.
KLINISCHE PADIATRIE, 2015, 227 (6-7): : 329 - 334
[22] Allopurinol Use During Maintenance Therapy for Acute Lymphoblastic Leukemia Avoids Mercaptopurine-related Hepatotoxicity
Giamanco, Nicole M.
Cunningham, Bethany S.
Klein, Laura S.
Parekh, Dina S.
Warwick, Anne B.
Lieuw, Kenneth
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2016, 38 (02) : 147 - 151
[23] Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy
Ostergaard, Anna
Bohnstedt, Cathrine
Grell, Kathrine
Degn, Matilda
Zeller, Bernward
Taskinen, Mervi
Hafsteinsdottir, Solveig
Bjorgvinsdottir, Helga
Heyman, Mats
Hoogerbrugge, Peter
Schmiegelow, Kjeld
LEUKEMIA, 2021, 35 (03) : 863 - 866
[24] Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy
Anna Østergaard
Cathrine Bohnstedt
Kathrine Grell
Matilda Degn
Bernward Zeller
Mervi Taskinen
Solveig Hafsteinsdottir
Helga Björgvinsdóttir
Mats Heyman
Peter Hoogerbrugge
Kjeld Schmiegelow
Leukemia, 2021, 35 : 863 - 866
[25] Adherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia
Alsous, Mervat
Abu Farha, Rana
Alefishat, Eman
Al Omar, Suha
Momani, Deema
Gharabli, Alia
McElnay, James
Horne, Robert
Rihani, Rawad
PLOS ONE, 2017, 12 (09):
[26] RELAPSE FACTORS DURING MAINTENANCE THERAPY OF ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDREN
HAYDER, S
BJORK, O
NILSSON, B
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1992, 9 (01) : 21 - 27
[27] Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia
Schmiegelow, K
Björk, O
Glomstein, A
Gustafsson, G
Keiding, N
Kristinsson, J
Mäkipernaa, A
Rosthoj, S
Szumlanski, C
Sorensen, TM
Weinshilboum, R
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) : 1332 - 1339
[28] Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia
Schmiegelow, K
Ifversen, M
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1996, 13 (05) : 433 - 441
[29] The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia
Kloos, Robin Q. H.
Pieters, Rob
van den Bos, Cor
van Eijkelenburg, Natasha K. A.
de Jonge, Robert
van der Sluis, Inge M.
LEUKEMIA & LYMPHOMA, 2019, 60 (12) : 3002 - 3010
[30] Incidence and determinants of hematotoxicity in acute lymphoblastic leukemia children who received 6-mercaptopurine based maintenance therapy in Addis Ababa, Ethiopia
Ali, Awol Mekonnen
Adam, Haileyesus
Hailu, Daniel
Coenen, Marieke J. H.
Howe, Rawleigh
Abula, Teferra
PLOS ONE, 2023, 18 (06):

← 1 2 3 4 5 →